title: Which patients with paroxysmal nocturnal hemoglobinuria (PNH) should be treated with eculizumab? ASH evidence-based review 2008.
authors.affiliation: Beth Israel Deaconess Hospital, Department of Pathology, Boston, MA 02215, USA. haspelr@yahoo.com
authors.forename: Richard L
authors.initials: RL
authors.lastname: Haspel
authors.forename: Peter
authors.initials: P
authors.lastname: Hillmen
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D005260:Female; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D012196:Review Literature as Topic; D013923:Thromboembolism / Q000139:chemically induced
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C481642:eculizumab